Global Health Economics Group

The activities of the Global Health Economics Group range from conducting economic evaluations of healthcare interventions, to analyses of the markets for health products and evaluations of the impacts of health-related shocks and healthcare policies on socio-economic indicators, human behaviour and health, including mental health. The group has a specific focus on infectious diseases in low-and middle-income settings. To carry out their research, the group applies a range of econometric approaches, including quasi-experimental methods and choice models. 

Group projects

• “Vaccine for prevention and treatment of Trypanosoma cruzi infection (CRUZIVAX)”.
• “Fast and reliable easy-to-use diagnostics for eliminating Bilharzia in young children and mothers (FreeBILy)”.
• “Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic (ORCHESTRA)”.
• “Prevention and management tools for reducing antibiotic resistance in high prevalence settings (REVERSE)”.
• “Indo-European Consortium for Next Generation Influenza Vaccine Innovation (INCENTIVE)”.

Sicuri E, Ramponi F, Lopes-Rafegas I, Saúte F. A broader perspective on the economics of malaria prevention and the potential impact of SARS-CoV-2. Nat Commun. 2022 May 13;13(1):2676. doi: 10.1038/s41467-022-30273-z.

Cirera L, Vall Castelló J, Brew J, Saúte F, Sicuri E. “The impact of a malaria elimination initiative on school outcomes: Evidence from Southern Mozambique”. Economics and Human Biology. 11/12/2021. Doi: 10.1016/j.ehb.2021.101100. 

Ramponi F, Aerts C, Sartor P, Pinazo MJ, Freilij H, Guzmán CA, Malchiodi E, Sicuri E. Development of vaccines for Chagas disease (CRUZIVAX): stakeholders' preferences and potential impacts on healthcare. Gac Sanit. 2022 Dec 21;37:102275. doi: 10.1016/j.gaceta.2022.102275. 

Aerts C; Barrenho E, Miraldo M, Sicuri, E. “The Impact of the Priority Review Voucher on Research and Development for Tropical Diseases”. Pharmaceutical Medicine. 19/05/2022. Doi: 10.1007/s40290-022-00427-x. 

Scherif Adegnika O, Josiane Honkpehedji Y, Mougeni Lotola F, Todagbe Agnandji S, Akim Adegnika A, Lell B, Sicuri E. Funding patterns for biomedical research and infectious diseases burden in Gabon. BMC Public Health. 24/11/2021. Doi: 10.1186/s12889-021-12201-w. 

Thomas R, Cirera L, Brew J, Saúte F, Sicuri E. The short-term impact of a malaria elimination initiative in Southern Mozambique: Application of the synthetic control method to routine surveillance data. Health Economics. 08/06/2021. Doi: 10.1002/hec.4367. 

Aerts C, Vink M, Pashtoon SJ, Nahzat S, Picado A, Cruz I, Sicuri E, Cost-effectiveness of new diagnostic tools for cutaneous leishmaniasis in Afghanistan, Appl Health Econ Health Policy. 2018 Nov 21. doi: 10.1007/s40258-018-0449-8.

Aerts C, Sunyoto T, Tediosi F, Sicuri E. Are public-private partnerships the solution to tackle neglected tropical diseases? A systematic review of the literature. Health Policy. 2017 Jul;121(7):745-754.

Alonso S, Munguambe K, Sicuri E. Market for Artemether-Lumefantrine to treat childhood malaria in a district of southern Mozambique. Health Econ. 2017 Dec;26(12):e345-e360.

Requena-Méndez A, Bussion S, Aldasoro E, Jackson Y, Angheben A, Moore D, Pinazo MJ, Gascón J, Muñoz J, Sicuri E. Cost-effectiveness of Chagas disease screening in Latin American migrants at primary health-care centres in Europe: a Markov model analysis, Lancet Glob Health. 2017 Apr;5(4):e439-e447.